Tyra Biosciences, Inc.

18.20 USD
-0.06 (-0.33%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tyra Biosciences, Inc. stock is up 24.15% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 11 May’s closed higher than April. 100% of analysts rate it a buy.

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

  • Oppenheimer
    Mon May 13, 08:37
  • Wedbush
    Fri May 10, 09:43
  • HC Wainwright & Co.
    Fri May 10, 07:39